IHAM
JANX icon

Integral Health Asset Management’s Janux Therapeutics JANX Stock Holding History

Integral Health Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$10.7M – 96
2024
Q4 		$10.7M Buy
+200,000
New +$10.6M 0.91% 41

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Integral Health Asset Management's JANX Position: Q1 2025 in Review

Integral Health Asset Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 200,000 shares — an estimated $10.7M sold.

Integral Health Asset Management first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $10.7M in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Integral Health Asset Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 200,000 Janux Therapeutics shares in Q1 2025, an estimated $10.7M.
  • Integral Health Asset Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Integral Health Asset Management's Janux Therapeutics position peaked at $10.7M in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.